Clinical Trial Update: Long Term Safety of Amifampridine Phosphate in Spinal Muscular Atrophy 3 [Phase 2]

View source ↗

Summary

Phase 2 long-term safety trial of amifampridine phosphate in spinal muscular atrophy type 3 has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy Type

Drugs mentioned

• Amifampridine phosphate (amifampridine phosphate)

Snippet

Sponsor: Catalyst Pharmaceuticals, Inc. | Conditions: Spinal Muscular Atrophy Type 3 | Phase 2 | Status: TERMINATED | Results posted: 2023-11-30